A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.